Prasugrel NEW
| Price | $37 | $52 | $129 |
| Package | 50mg | 100mg | 500mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: Prasugrel | CAS No.: 150322-43-3 |
| Purity: 99.86% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | Prasugrel |
| Description | Prasugrel (CS-747) is a piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS. |
| In vitro | Prasugrel has a faster, higher and more reliable platelet aggregation inhibitory effect than clopidogrel and is metabolized in vivo to an active metabolite with selective P2Y(12) antagonistic activity. |
| In vivo | Prasugrel has a faster, higher and more reliable platelet aggregation inhibitory effect than clopidogrel and is metabolized in vivo to an active metabolite with selective P2Y(12) antagonistic activity. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 83.33 mg/mL (223.14 mM), Sonication is recommended. 10% DMSO+90% Saline : < 8.33 mg/mL (22.31 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 8.33 mg/mL (22.31 mM), Solution. |
| Keywords | Prasugrel | platelet | PCR-4099 | PCR4099 | P2YReceptor | P2Y12 | P2Y Receptor | P2Y | metabolite | LY-640315 | LY 640315 | Inhibitor | inhibit | CS747 | CS 747 | antiplatelet | aggregation | ADP | active |
| Inhibitors Related | Clopidogrel | Prasugrel Hydrochloride | Sodium metatungstate | Regrelor disodium | (±) Clopidogrel hydrogen sulfate | Uridine-5'-diphosphate disodium salt | Uridine triphosphate trisodium salt | ATPγS tetralithium salt | P2Y1/P2Y12 antagonist-1 | Ticagrelor | Diquafosol tetrasodium | cangrelor tetrasodium |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-06-09 | ||
| $37.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-06-02 | |
| $37.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-06-02 | |
| $1.00 |
Hebei Chuanghai Biotechnology Co., Ltd
|
2026-03-20 | ||
| $1.10 |
VIP6Y
|
Dideu Industries Group Limited
|
2025-11-18 | |
| $15.00 |
Ouhuang Engineering Materials (Hubei) Co., Ltd
|
2024-04-24 | ||
| $1.00 |
ANHUI SHENGZHIKAI BIOTECHNOLOGY CO.,LTD
|
2024-04-15 | ||
| $30.00 |
Anhui Ruihan Technology Co., Ltd
|
2023-08-23 | ||
| $100.00 |
Henan Bao Enluo International TradeCo.，LTD
|
2023-08-02 | ||
| $10.00 |
Anhui Rencheng Technology Co., Ltd
|
2023-01-12 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY